We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Preattached Holder Protects Phlebotomists Against Needlestick Injury

By LabMedica International staff writers
Posted on 08 Jun 2010
A push button blood collection set with a preattached holder is now available to protect health care workers from accidental needlestick injuries (NSIs). More...
The ready-to-use product will also prevent reuse of the tube holder.

Needlestick and sharps injuries carry the risk of infections and are an occupational hazard for all healthcare professionals involved in clinical care. The preassembled device saves time by shortening the blood collection process; the preattached holder covers the holder end of the needle, reducing the risk of injury.

The intuitively designed apparatus consists of a large flexible wing flanking the needle, a push button safety mechanism, and tubing that does not kink or coil. This is connected to the single use holder by way of a luer adaptor. The blood collection set is manufactured by Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) and is an improved version of the original Vacutainer collection sets. The new product's in-vein activation of the safety device provides split-second protection against NSIs.

Tube holders that are reused have not been disinfected or sterilized, posing unnecessary exposure to blood borne pathogens including human immunodeficiency virus (HIV), hepatitis C virus, and hepatitis B virus. The National Phlebotomy Association (NPA; Landover, MD, USA) recently completed a study on reusable blood tube holders. The study revealed that 99% of holders sampled, were contaminated with blood. This poses an occupational exposure risk to the healthcare worker and an infection-control exposure risk to the patient.

Single-use holders that are preattached to safety-engineered blood collection needles may provide the highest level of infection prevention for the healthcare industry. One hospital reported an 88% reduction in NSIs after adopting the device, with zero NSIs in the final 21 months after implementing the product.

Dr. Ana Stankovic, M.D, Ph.D., M.S.P.H., world VP at BD diagnostics said, "this product virtually eliminates a healthcare worker's exposure to a contaminated needle and reduces the time required to collect blood for diagnostic testing."

Related Links:

Becton, Dickinson and Company
National Phlebotomy Association



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.